Zobrazeno 1 - 10
of 1 232
pro vyhledávání: '"drug survival"'
Dupilumab in Patients with Atopic Dermatitis: A Multicentric, Long-Term, Real-World Portuguese Study
Autor:
Tiago Torres, Maria João Cruz, Margarida Gonçalo, Paulo Filipe, Bruno Duarte, João Alves, José Miguel Alvarenga, Gilberto Rosa, Duarte Flor, José Ramos, Diogo Sousa, Aureliu Rosca, César Magalhães, Cristina Claro, Joana Rocha, Catarina Vilarinho, Fernando Mota, Alberto Mota, Maria João Paiva Lopes
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 8, Pp 2209-2221 (2024)
Abstract Introduction Several clinical trials have established the efficacy and safety of dupilumab for treating atopic dermatitis (AD). However, literature remains scarce in reporting the long-term effectiveness, safety, and drug survival of dupilum
Externí odkaz:
https://doaj.org/article/6c3eb3f5268e43d09777d0ea3da93227
Autor:
Bucur S, Serban ED, Ileanu BV, Costache RS, Nicolescu AC, Constantin T, Costache DO, Constantin MM
Publikováno v:
Psoriasis: Targets and Therapy, Vol Volume 14, Pp 79-86 (2024)
Stefana Bucur,1,2 Elena-Daniela Serban,1 Bogdan Vasile Ileanu,3 Raluca Simona Costache,4,5 Alin Codrut Nicolescu,6 Traian Constantin,7,8 Daniel Octavian Costache,1,9 Maria-Magdalena Constantin1,2 1 2nd Department of Dermatology, “Carol Davila” Un
Externí odkaz:
https://doaj.org/article/15ed3da1699d4e038bd4453aa26fa752
Autor:
Oh Chan Kwon, Wonho Choi, Soo Min Ahn, Ji Seon Oh, Seokchan Hong, Chang-Keun Lee, Bin Yoo, Min-Chan Park, Yong-Gil Kim
Publikováno v:
Advances in Rheumatology, Vol 64, Iss 1, Pp 1-7 (2024)
Abstract Background To assess the drug survival and change of disease activity using a second Janus kinase inhibitor (JAKi) after failure to a JAKi and subsequent biologic disease-modifying anti-rheumatic drugs (bDMARDs) in patients with difficult-to
Externí odkaz:
https://doaj.org/article/1d89bb57492641979a2490dcae8c0761
Autor:
Fatma Elif Yıldırım, Fatma Aslı Hapa
Publikováno v:
Advances in Dermatology and Allergology, Vol 41, Iss 1, Pp 49-55 (2024)
Externí odkaz:
https://doaj.org/article/120816b07f4c4833bcf2424d50d3f4e3
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract Biologics for psoriasis are efficient and safe, but very expensive. We investigated the association of the reducing copayment program (RCP) with changes in biologics use patterns depending on the income levels of patients with moderate-to-se
Externí odkaz:
https://doaj.org/article/d6834e77579f4d139a4e0a1377b0e9f1
Autor:
Giacomo Caldarola, Marco Galluzzo, Nicoletta Bernardini, Elisabetta Botti, Eleonora De Luca, Clara De Simone, Marco Mariani, Gaia Moretta, Sabatino Pallotta, Elena Campione, Ketty Peris
Publikováno v:
Dermatology Practical & Conceptual, Vol 14, Iss 2 (2024)
Introduction: Data about the long-term effectiveness of brodalumab could be valuable in assessing patient adherence to treatment and improving psoriasis management. Objective: The aim of our study was to evaluate the drug survival of brodalumab and
Externí odkaz:
https://doaj.org/article/c12852da8d7849db875d715e15d620bf
Autor:
Russo F, Galluzzo M, Stingeni L, Persechino S, Zichichi L, Conti A, Giofrè C, Dini V, Vispi M, Atzori L, Cattaneo A, Parodi A, Bardazzi F, Stinco G, Dapavo P, Girolomoni G, Musumeci ML, Papini M, Venturini M, Dastoli S, Di Nuzzo S, Fargnoli MC, Pagnanelli G, Bernardini N, Gambini DM, Malagoli P, Mazzatenta C, Peris K, Zalaudek I, Fabbrocini G, Loconsole F, Vassallo C, Pietroleonardo L, Prignano F, Franchi C, Offidani AM, Bonifati C, Di Lernia V, Gigante G, Bartezaghi MS, Franchi M, Ursoleo P, Aloisi E
Publikováno v:
Clinical, Cosmetic and Investigational Dermatology, Vol Volume 16, Pp 3561-3574 (2023)
Filomena Russo,1 Marco Galluzzo,2,3 Luca Stingeni,4 Severino Persechino,5 Leonardo Zichichi,6 Andrea Conti,7 Claudia Giofrè,8 Valentina Dini,9 Martina Vispi,10 Laura Atzori,11 Angelo Cattaneo,12 Aurora Parodi,13 Federico Bardazzi,14 Giuseppe Stinco,
Externí odkaz:
https://doaj.org/article/115768c008944ac5b86654ed48f517a0
Autor:
Vered Rosenberg, Howard Amital, Gabriel Chodick, Freddy Faccin, Abdulla Watad, Dennis McGonagle, Omer Gendelman
Publikováno v:
Journal of Clinical Medicine, Vol 13, Iss 15, p 4480 (2024)
Objectives: The objective of this study was to evaluate the real-world drug survival, adherence, and discontinuation risk of biologics disease-modifying anti-rheumatic drugs (bDMARDs) among patients with ankylosing spondylitis (AS). Methods: This was
Externí odkaz:
https://doaj.org/article/98393aaba5e645729714876aa2e94844
Autor:
Alexandra-Diana Diaconu, Cristina Pomîrleanu, Mara Russu, Georgiana Strugariu, Eugen Ancuța, Irina Ciortescu, Cristina Bologa, Bianca Codrina Morărașu, Mihai Constantin, Alexandr Ceasovschih, Victorița Șorodoc, Laurențiu Șorodoc, Codrina Ancuța
Publikováno v:
Journal of Personalized Medicine, Vol 14, Iss 4, p 417 (2024)
(1) Objective: The main aims of our study were to explore the drug survival and effectiveness of secukinumab in patients with axial spondyloarthritis (axSpA). (2) Methods: We underwent a retrospective analysis of consecutive axSpA treated with secuki
Externí odkaz:
https://doaj.org/article/11d8cb7959764f508e1a39b91e1849ca
Autor:
Niccolò Gori, Alvise Sernicola, Ersilia Tolino, Maria Mariano, Marco Galluzzo, Gaia Moretta, Rosa Coppola, Andrea D’Alessio, Massimo Sansone, Virginia Maffei, Claudia Paolino, Cristian Ferrao, Lauro Cascia, Paola Addio, Lucia Di Nardo, Andrea Chiricozzi, Ester Del Duca, Antonio Cristaudo, Luca Bianchi, Sabatino Pallotta, Vincenzo Panasiti, Giovanni Pellacani, Concetta Potenza, Ketty Peris
Publikováno v:
Journal of Dermatological Treatment, Vol 34, Iss 1 (2023)
Objectives The purpose of this study was to analyze the drug survival rate of dupilumab up to 2 years in a large real-world cohort of adult patients affected by moderate/severe atopic dermatitis (AD), and to investigate the clinical, demographic and
Externí odkaz:
https://doaj.org/article/b53505b790e34e229d8174bf1e7755f4